和 訳
[2605A-1] 初級
こちらを読んで、以下を翻訳してみよう。 |
Pulmonary arterial hypertension (PAH) is a relatively rare yet complex disorder associated with impaired quality of life and increased mortality. 1,2 Patients with PAH are sub-classified by the World Health Organization (WHO) into 5 groups based on etiology. 3 Patients in WHO Group 1 PAH are hemodynamically defined by a mean pulmonary artery pressure (mPAP) > 20 mmHg at rest, pulmonary arterial wedge pressure (PAWP) of ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 2 Wood units by right heart catherization. 3,4 Causes of the WHO Group 1 subtype include drug- or toxin-induced, heritable, or may be associated with other conditions.
|
|
[2605A-2] 初級
こちらを読んで、以下を翻訳してみよう。 |
Sotatercept, a subcutaneous injection and fusion protein, targets a new pathway to reduce endothelial proliferation, thus adding a new pharmacotherapeutic option while improving clinical outcomes in addition to existing therapies. Based on available evidence, sotatercept may be a reasonable therapeutic addition in the management of WHO Group 1 FC II-III patients to further improve symptoms, particularly in those on background triple therapy. Presently, there is no evidence to support sotatercept as a first-line agent or monotherapy.
|
|
|
|
|
|
|